C4 Therapeutics, Inc. (CCCC): A Bull Case Theory [Yahoo! Finance]
C4 Therapeutics, Inc. (CCCC)
NASDAQ:AMEX Investor Relations:
ir.chinacache.com
Company Research
Source: Yahoo! Finance
C4 Therapeutics, Inc.'s share was trading at $1.9600 as of January 29th. Copyright: dolgachov / 123RF Stock Photo C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins, stands at the forefront of targeted protein degradation (TPD), a next-generation approach in precision oncology that eliminates disease-causing proteins rather than inhibiting them. Unlike traditional small molecules, degraders achieve deeper, more durable therapeutic effects by fully removing their targets. C4's proprietary E3 ligase platform chemistry, protected by robust intellectual property and validated by partnerships with Pfizer and Biogen, has transformed theoretical TPD science into a repeatable, data-driven drug engine. Its TORPEDO platform enables rational degrader design and rapid optimization through in silico modeling, shortening development cycles and deepening its competitive moat. Strategically, C4 focuses o
Show less
Read more
Impact Snapshot
Event Time:
CCCC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CCCC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CCCC alerts
High impacting C4 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CCCC
News
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]Yahoo! Finance
- C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewswire
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Odyssey Therapeutics Appoints Jolie M. Siegel as Executive Vice President, General Counsel [Yahoo! Finance]Yahoo! Finance
CCCC
Earnings
- 11/6/25 - Beat
CCCC
Sec Filings
- 1/16/26 - Form 4
- 1/14/26 - Form 8-K
- 1/5/26 - Form 4
- CCCC's page on the SEC website